2024 Nasdaq atai - NEW YORK, Dec. 16, 2020 /PRNewswire/ -- atai Life Sciences ('atai' or the 'Company'), a global biotech company developing psychedelic and non-psyc... NEW YORK, Dec. 16, 2020 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company"), a gl...

 
Clinical-stage biopharmaceutical company Atai Life Sciences (NASDAQ:ATAI) declared that it has signed a term loan agreement with Hercules Capital, Inc. for a maximum amount of $175 million.. Nasdaq atai

Find the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com. ... Nasdaq Insider Activity page provides trading information of corporate insiders (officers ...Shares in Peter Thiel-backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling back some.Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Investors In Q2 2023: 7 Atai Life Sciences N.V. (NASDAQ:ATAI) is a biotechnology company developing treatments for mental health disorders.ATAI Life Sciences N.V. Common Shares (ATAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.DarioGaona/iStock via Getty Images. Atai Life Sciences (NASDAQ:ATAI) has been making great progress in advancing several drugs from its pipeline on multiple fronts.In particular, it is advancing a ...First, MindMed (Nasdaq: MNMD, NEO: MMED) will present data from their Phase 2a clinical trial attempting to treat Generalized Anxiety Disorder using a large dose of LSD paired with therapy.. For serious MindMed investors, this will be a big moment. While in the short to medium-term stocks can fluctuate wildly, especially speculative biotech …View the latest ATAI Life Sciences N.V. (ATAI) stock price, news, historical charts, analyst ratings and financial information from WSJ.Based on analysts offering 12 month price targets for ATAI in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . On the other hand, atai (NASDAQ:ATAI)’s Phase 1 clinical trial testing atypical opioid receptor modulator KUR-101 towards Opioid Use Disorder treatment has provided mixed results, which seem to ...Atai Life Sciences N.V. (NASDAQ: ATAI) took a significant step to bolster its partnership with IntelGenx Technologies Corp. . The medical technology firm, Atai, now owns a substantial 63% stake in ...NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to ...He was also CFO of atai Life Sciences (Nasdaq: ATAI), completing over $282M in late-stage private financings and led a successful $258M IPO at a $2.3B valuation to support the acquisition of ...Atai Life Sciences (NASDAQ: ATAI) $1.12 (7.7%) $0.08 Price as of December 1, 2023, 4:00 p.m. ET Overview News & Analysis Financial Health Valuation Related Stocks Key Data …Shares of Atai Life Sciences ( ATAI 7.69%), a clinical-stage biopharmaceutical company that is developing therapies from psychedelics to treat mental health conditions, saw its shares rise 12.41% ...Other companies interested in the use of traditional, naturally derived ibogaine for substance abuse include DemeRx, a subsidiary of Peter Thiel-backed Atai Life Sciences (NASDAQ:ATAI), and ...Nov 10, 2022 · atai ended the third quarter of 2022 with a cash position of $304.1 million, which combined with committed funding from the Hercules loan facility, is anticipated to provide cash runway into 2025 ... ATAI Life Sciences N.V. Common Shares ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Atai Life Sciences N.V. (NASDAQ:ATAI) is a promising clinical-stage biopharmaceutical company that creates and funds businesses focusing on developing psychedelic-based treatments.May 25, 2023 · ATAI Life Sciences (NASDAQ: ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ... NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...Stock Price & Overview 3.84K followers $1.07 -0.05 ( -4.46%) 4:00 PM 11/21/23 NASDAQ | $USD | Post-Market: $1.11 +0.04 (+3.74%) 7:59 PM Summary Ratings Financials …I’ve also been asked if it’s proper and ethical that COMPASS Pathways (Nasdaq: CMPS) and atai Life Sciences (Nasdaq: ATAI) own the majority of the patents around those psychedelics.Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...May 25, 2023 · ATAI Life Sciences (NASDAQ: ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ... ATAI. 1.095. +2.34%. Webull offers ATAI Ent Holdg (ATAI) historical stock prices, in-depth market analysis, NASDAQ: ATAI real-time stock quote data, in-depth charts, free ATAI options chain data, and a fully built financial calendar to help you invest smart. Buy ATAI stock at Webull.Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...Find the latest SEC Filings data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Find the latest SEC Filings data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Atai Life Sciences (Nasdaq: ATAI) Always at the top of the list of psychedelics companies on the move, Atai Life Sciences launched a Phase 1 study of an MDMA derivative focusing on post-traumatic stress disorder in September.He was an early stakeholder in Atai Life Sciences (NASDAQ:ATAI), a startup with 10 psychedelic programs in the works and that count Peter Thiel as one of its primary investors.I’ve also been asked if it’s proper and ethical that COMPASS Pathways (Nasdaq: CMPS) and atai Life Sciences (Nasdaq: ATAI) own the majority of the patents around those psychedelics.Atai Life Sciences N.V. (NASDAQ:ATAI) was down, falling 38% to $1.63 after the company announced Perception Neuroscience's Phase 2a clinical trial did not meet its primary endpoint.atai ended the third quarter of 2022 with a cash position of $304.1 million, which combined with committed funding from the Hercules loan facility, is anticipated to provide cash runway into 2025 ...Summary Real-Time After-Hours Pre-Market Charts NEWS & ANALYSIS News Press Releases Analyst Research ATAI ATAI REAL TIME ATAI Real-Time Quotes 1D 5D 1M 6M YTD 1Y 5Y MAX Last Five Real-Time...NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the …In this article, we discuss the 10 best psychedelic stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Psychedelic Stocks to Buy Now. Psychedelic treatments for mental health disorders like depression, anxiety, and post-traumatic stress have revolutionized the industry in the past few […]The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ...atai Impact, the philanthropic program of atai Life Sciences (NASDAQ: ATAI) and the Multidisciplinary Association for Psychedelic Studies (MAPS) recently announced a $500,000 donation from atai ...ATAI Life Sciences (Nasdaq: ATAI) atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT: The trial is a randomized, double-blind, placebo-controlled study designed to evaluate the relative bioavailability of buccal versus IV formulations, ...ATAI Life Sciences Stock (NASDAQ:ATAI), Guidance and Forecast benzinga.com - August 13 at 4:19 AM: ATAI Life Sciences Stock (NASDAQ:ATAI), Short Interest Report benzinga.com - August 12 at 11:19 PM: ATAI Life Sciences (ATAI) Receives a Buy from Berenberg Bank markets.businessinsider.com - August 11 at 5:09 PMNEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Find the latest Earnings Report Date for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Nov 17, 2023 ... atai Life Sciences N.V. (ATAI) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy).Stock Price & Overview 3.84K followers $1.07 -0.05 ( -4.46%) 4:00 PM 11/21/23 NASDAQ | $USD | Post-Market: $1.11 +0.04 (+3.74%) 7:59 PM Summary Ratings Financials …Jan 9, 2023 · NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to ... NASDAQ Health Care/Life Sciences Compare to Open 1.12 Prior Close 1.09 (11/22/23) 1 Day ATAI 0.92% DJIA 0.33% Russell 2K 0.67% Health Care/Life Sciences 0.32% …Mar 6, 2023 · NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... Analyst's Opinion · Consensus Rating. Atai Life Sciences has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' ...Atai Life Sciences (NASDAQ:ATAI) closed at $1.29, almost the same as Friday 22’s closing price $1.30 and also down from past weeks’ closings ($1.45 and $1.43.)The Trade: Atai Life Sciences N.V. (NASDAQ:ATAI) Florian Brand acquired a total of 20,000 shares at an average price of $1.16. The insider spent around $23,120 to buy those shares.Atai Life Sciences (NASDAQ:ATAI) closed at $1.06, down from prior weeks’ closings at $1.3, $1.28, $1.39 and $1.29. Incannex Healthcare (NASDAQ:IXHL) closed at $0.99, up from prior week’s close ...Shares in Peter Thiel-backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling back some.Instrument Name Atai Life Sciences N.V. Instrument Symbol (ATAI-Q). Instrument Exchange NASDAQ ; Previous Close 1.1200 ; 52-Week High/Low 3.6500 1.0400 ; Volume ...Mar 29, 2023 · Furthermore, atai owns 22.4% of COMPASS Pathways, a psilocybin-focused, Nasdaq-listed biotech company. This stake is worth roughly $98M as of Tuesday, March 28, based on COMPASS Pathways ... October 6, 2023. NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inau... atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ...Through its subsidiary Perception Neuroscience, atai Life Sciences N.V. (NASDAQ:ATAI) recently released an update on another platform for treatment resistant depression (TRD) ...Here are our picks for the five psychedelic companies to watch in 2022: Atai Life Sciences, Berlin, Germany – listed on NASDAQ (ATAI) since July, 2021 – Market cap $999 million. Atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is also one of the largest shareholders ...atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet ...atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health …As of August 2, 2023, the average one-year price target for ATAI Life Sciences N.V. is 12.51. The forecasts range from a low of 5.15 to a high of $22.05. The average price target represents an ...Jan 9, 2023 · NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to ... Based on 2 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $20.00 with a high ...Oct 12, 2022 · NEW YORK and BERLIN, Oct. 12, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) announced today positive initial results for their Phase 1 clinical trial of KUR-101. KUR ... Atai Life Sciences (NASDAQ:ATAI) is one of the leading biotech companies discovering and developing treatments derived from psychedelic compounds.Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company transforming the treatment of mental health disorders. On January 12, the company announced that the Food and Drug Administration (FDA) gave the company Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R …Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...Nov 29, 2023 · According to 4 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 1,110.76% from the latest price. Nov 21, 2023 · Atai Life Sciences The Trade : Atai Life Sciences N.V. (NASDAQ:ATAI) Florian Brand acquired a total of 20,000 shares at an average price of $1.16. The insider spent around $23,120 to buy those shares. Sep 21, 2021 · NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ... ATAI Life Sciences N.V. Common Shares (ATAI) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. NVIDIA Corporation Common Stock. ATAI Life Sciences N ... NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders ...NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R …NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming …1Y 5Y No 1Y chart data available About ATAI ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and …The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ...NASDAQ: ATAI LIFE SCIENCES N.V. Instrumentos de la emisora ATAI LIFE SCIENCES N.V. Tipo Valor Serie Isin Estatus Descripción; 1A: N: NL0015000DX5: ACTIVA: ACCIONES SISTEMA INTERNACIONAL DE COTIZACIONES: Estados Financieros. Puede adquirir los reportes financieros trimestrales completos de esta emisora en nuestras .Atai Life Sciences (NASDAQ:ATAI) closed at $1.29, almost the same as Friday 22’s closing price $1.30 and also down from past weeks’ closings ($1.45 and $1.43.)ATAI Life Sciences Stock (NASDAQ:ATAI), Guidance and Forecast benzinga.com - August 13 at 4:19 AM: ATAI Life Sciences Stock (NASDAQ:ATAI), Short Interest Report benzinga.com - August 12 at 11:19 PM: ATAI Life Sciences (ATAI) Receives a Buy from Berenberg Bank markets.businessinsider.com - August 11 at 5:09 PMOn February 16, Atai Impact, the philanthropic program of Atai Life Sciences (NASDAQ:ATAI) announced it has donated $500,000 to the Multidisciplinary Association for Psychedelic Studies (MAPS ...The new research reports from Fundamental Markets, available for free download at the links above, examine Whiting Petroleum Corporation (NYSE:WLL), ATA Inc. (NASDAQ:ATAI), Ubiquiti Networks, Inc ...(Part four of a four-part series) See previous stories in this series: Insider's Peek At Mammoth Of Psychedelics VCs, Palo S...The latest price target for ATAI Life Sciences ( NASDAQ: ATAI) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 20.00 expecting ATAI to rise ...ATAI Life Sciences NV Follow Share $1.11 Nov 22, 2:08:38 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Cybin Inc $0.46 CYBN2.61% Compass Pathways PLC $6.00 CMPS2.92% Mind Medicine...Nasdaq atai

ATAI Life Sciences NV (NASDAQ:ATAI) ATAI Life Sciences NV. 1.07. Delayed Data. As of 3:58pm ET. -0.055 / -4.91%. Today’s Change. 1.05. Today ||| 52-Week Range. . Nasdaq atai

nasdaq atai

Jan 9, 2023 · NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to ... Atai Life Sciences (NASDAQ:ATAI) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior business?We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...senior director of external affairs @ atai life sciences (nasdaq: atai ...One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...Nov 29, 2023 · 4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price. To obtain more information or to obtain a copy of the early warning report filed in respect of this press release, please contact atai by email at [email protected] or by mail at c/o atai Life Sciences ...Clinical-stage biopharma company atai Life Sciences (NASDAQ:ATAI) announced the dosing of the first subject in majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to ...How much insider buying is happening at Atai Life Sciences? Insiders have purchased a total of 1,618,685 ATAI shares in the last 24 months for a total of $3,116,715.96 bought.ATAI Life Sciences News: This is the News-site for the company ATAI Life Sciences on Markets Insider Indices Commodities Currencies StocksNov 14, 2023 · The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ... As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.May 25, 2023 · ATAI Life Sciences (NASDAQ:ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ... NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences (ATAI-1.75%) is having a rough go of things lately ...On September 27, ATAI Life Sciences (NASDAQ:ATAI), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of PTSD and other indications, announced ...He was also CFO of atai Life Sciences (Nasdaq: ATAI), completing over $282M in late-stage private financings and led a successful $258M IPO at a $2.3B valuation to support the acquisition of ...Aug 8, 2023 · NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... DarioGaona/iStock via Getty Images. Atai Life Sciences (NASDAQ:ATAI) has been making great progress in advancing several drugs from its pipeline on multiple fronts.In particular, it is advancing a ...ATAI Life Sciences (NASDAQ: ATAI) is another clinical-stage biotech looking to make a mark in the mental health space. Its stock took a dive recently following failed results of its Phase 2a study ...Based on 2 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $20.00 with a high ...Atai Life Sciences unit GABA Therapeutics upbeat about deuterated form of 1960s drug. The biopharma Atai Life Sciences (Nasdaq:ATAI) subsidiary GABA Therapeutics is sharing positive results from a Phase 1 study of GRX-917, a deuterated form of etifoxine, which the German firm Hoechst developed in the 1960s. Sanofi-Aventis …Oct 31, 2023 · Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Investors In Q2 2023: 7 Atai Life Sciences N.V. (NASDAQ:ATAI) is a biotechnology company developing treatments for mental health disorders. Analyst's Opinion · Consensus Rating. Atai Life Sciences has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' ...Atai Life Sciences N.V. (NASDAQ: ATAI) took a significant step to bolster its partnership with IntelGenx Technologies Corp. . The medical technology firm, Atai, now owns a substantial 63% stake in ...Dec 23, 2022 · NEW YORK and BERLIN, Dec. 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical stage biopharmaceutical company aiming to transform the ... We are currently testing DMX-1002, atai’s oral formulation of ibogaine, in an ongoing Phase 1/2 trial to evaluate its safety, tolerability, pharmacokinetics, and efficacy. We expect initial data ...atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates. “As the burden of unmet medical needs in mental health care continues to grow, our team remains …Find the latest Earnings Report Date for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.ATAI Life Sciences News: This is the News-site for the company ATAI Life Sciences on Markets Insider Indices Commodities Currencies StocksThe Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...ATAI Life Sciences (NASDAQ: ATAI) is another clinical-stage biotech looking to make a mark in the mental health space. Its stock took a dive recently following failed results of its Phase 2a study ...ATAI Life Sciences (NASDAQ: ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders.The company has recently garnered ...Nov 29, 2023 · The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions. The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...ATAI Life Sciences (NASDAQ:ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ...NASDAQ Health Care/Life Sciences Compare to Open 1.12 Prior Close 1.09 (11/22/23) 1 Day ATAI 0.92% DJIA 0.33% Russell 2K 0.67% Health Care/Life Sciences 0.32% …Atai Life Sciences N.V. (NASDAQ:ATAI) AVROBIO, Inc. (NASDAQ:AVRO) Axsome Therapeutics, Inc. (NASDAQ:AXSM) (communicated in its earnings release a potential delay in approval of its major ...According to 4 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 1,110.76% from the latest price.ATAI Stock Price | ATAI Life Sciences N.V. Stock Quote (U.S.: Nasdaq ...Dec 13, 2021 · NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... Dec 13, 2021 · NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... 3:24 pm. Articles. atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) August 10, 2023 Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients…. August 10, 2023.With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...Let’s get straight to it: The psychedelic stock market continues to underperform. Taking a look at our Psychedelic Invest Index, we can see that only two companies that trade for a greater than $50 million market cap were up in the month of November: atai Life Sciences (ATAI) & GH Research (GHRS). Wait, there are...Find the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A novel innovation is psychedelic drug-assisted psychotherapy – the medically …Atai Life Sciences (NASDAQ:ATAI) has a recorded annual revenue of $230,000.00. How much profit does Atai Life Sciences generate each year? Atai Life Sciences (NASDAQ:ATAI) has a recorded net income of -$152.38 million.EVgo, Inc. (NASDAQ:EVGO) fell 14.3% to close at $16.19 following negative analyst coverage from Credit Suisse. Atai Life Sciences N.V. (NASDAQ:ATAI) dropped 13.8% to close at $12.85 following Q3 ...Mar 7, 2023 · According to 6 analyst offering 12-month price targets in the last 3 months, ATAI Life Sciences has an average price target of $15.33 with a high of $23.00 and a low of $9.00. Below is a summary ... Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix.. PsyProtix is a precision psychiatry company focused ...Nov 24, 2023 · The latest ATAI Life Sciences stock prices, stock quotes, news, and ATAI history to help you invest and trade smarter. ... (NASDAQ: ATAI) reported its financial results and corporate updates for ... Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights ...In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. ... NASDAQ: ATAI Atai Life Sciences. Market Cap. $173M. Today's Change (-7.14% ...Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company transforming the treatment of mental health disorders. On January 12, the company announced that the Food and Drug Administration (FDA) gave the company Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R …He was also CFO of atai Life Sciences (Nasdaq: ATAI), completing over $282M in late-stage private financings and led a successful $258M IPO at a $2.3B valuation to support the acquisition of ...NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Sep 21, 2021 · NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ... Quotes Summary Real-Time After-Hours Pre-Market Charts NEWS & ANALYSIS News Press Releases Analyst Research ATAI ATAI REAL TIME ATAI Real-Time Quotes 1D …Atai Life Sciences N.V. (ATAI) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Add to watchlist. 1.0900 +0.0200 (+1.87%) At close: 04:00PM EST. 1.1200 +0.03 …Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Investors In Q2 2023: 7 Atai Life Sciences N.V. (NASDAQ:ATAI) is a biotechnology company developing treatments for mental health disorders.The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st.... Form llc in delaware benefits